Cancer Research Cancer Epigenetics Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Artemov, D.
Right arrow Articles by Bhujwalla, Z. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Artemov, D.
Right arrow Articles by Bhujwalla, Z. M.
[Cancer Research 63, 2723-2727, June 1, 2003]
© 2003 American Association for Cancer Research

Advances in Brief

Magnetic Resonance Molecular Imaging of the HER-2/neu Receptor1

Dmitri Artemov2, Noriko Mori, Rajani Ravi and Zaver M. Bhujwalla

Departments of Radiology [D. A., N. M., Z. M. B.] and Oncology [R. R.], Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

The HER-2/neu receptor is a member of the epidermal growth factor family and is amplified in multiple cancers. It is under intense investigation both as a prognostic marker and for therapy, using monoclonal antibodies targeted against the receptor. We have developed a novel two-component gadolinium-based MR contrast agent to image the HER-2/neu receptor. Positive T1 contrast in MR images was generated by the specific binding of avidin-gadolinium complexes to tumor cells prelabeled with a biotinylated anti-HER-2/neu antibody. Significant intensity enhancement was observed in HER-2/neu-expressing cell lines and in vivo in a breast cancer model. Potential applications of this approach may include determination of the HER-2/neu status for prognosis and for selecting tumors for monoclonal antibody therapy.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
L. Yang, X.-H. Peng, Y. A. Wang, X. Wang, Z. Cao, C. Ni, P. Karna, X. Zhang, W. C. Wood, X. Gao, et al.
Receptor-Targeted Nanoparticles for In vivo Imaging of Breast Cancer
Clin. Cancer Res., July 15, 2009; 15(14): 4722 - 4732.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. S. Migalovich, V. Kalchenko, N. Nevo, G. Meir, F. Kohen, and M. Neeman
Harnessing Competing Endocytic Pathways for Overcoming the Tumor-Blood Barrier: Magnetic Resonance Imaging and Near-Infrared Imaging of Bifunctional Contrast Media
Cancer Res., July 1, 2009; 69(13): 5610 - 5617.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. Medarova, L. Rashkovetsky, P. Pantazopoulos, and A. Moore
Multiparametric Monitoring of Tumor Response to Chemotherapy by Noninvasive Imaging
Cancer Res., February 1, 2009; 69(3): 1182 - 1189.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Song, K. Shahverdi, D. L. Huso, Y. Wang, J. J. Fox, R. F. Hobbs, B. Gimi, K. L. Gabrielson, M. G. Pomper, B. M. Tsui, et al.
An Immunotolerant HER-2/neu Transgenic Mouse Model of Metastatic Breast Cancer
Clin. Cancer Res., October 1, 2008; 14(19): 6116 - 6124.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
J. E Burdette
In vivo imaging of molecular targets and their function in endocrinology
J. Mol. Endocrinol., June 1, 2008; 40(6): 253 - 261.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. A. Mankoff, J. M. Link, H. M. Linden, L. Sundararajan, and K. A. Krohn
Tumor Receptor Imaging
J. Nucl. Med., June 1, 2008; 49(Suppl_2): 149S - 163S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
Z. Cheng, O. P. De Jesus, M. Namavari, A. De, J. Levi, J. M. Webster, R. Zhang, B. Lee, F. A. Syud, and S. S. Gambhir
Small-Animal PET Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with Site-Specific 18F-Labeled Protein Scaffold Molecules
J. Nucl. Med., May 1, 2008; 49(5): 804 - 813.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
X. Wang, L. Yang, Z. Chen, and D. M. Shin
Application of Nanotechnology in Cancer Therapy and Imaging
CA Cancer J Clin, March 1, 2008; 58(2): 97 - 110.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
D. J. A. Margolis, J. M. Hoffman, R. J. Herfkens, R. B. Jeffrey, A. Quon, and S. S. Gambhir
Molecular Imaging Techniques in Body Imaging
Radiology, November 1, 2007; 245(2): 333 - 356.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
T. C. Chu, K. Y. Twu, A. D. Ellington, and M. Levy
Aptamer mediated siRNA delivery
Nucleic Acids Res., June 1, 2006; 34(10): e73 - e73.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
P. Workman, E. O. Aboagye, Y.-L. Chung, J. R. Griffiths, R. Hart, M. O. Leach, R. J. Maxwell, P. M. J. McSheehy, P. M. Price, and J. Zweit
Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.
J Natl Cancer Inst, May 3, 2006; 98(9): 580 - 598.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
J. T. Macgregor
Biomarkers of Cancer Risk and Therapeutic Benefit: New Technologies, New Opportunities, and Some Challenges
Toxicol Pathol, January 1, 2004; 32(1_suppl): 99 - 105.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.